# US 11,298,382 B2 · Bifidobacterium lactis BL-99 and application thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,298,382 B2
- Document ID: US11298382B2
- Status: Granted
- Kind: B2
- Application number: 17/217,305
- Filed: 2021-03-30
- Published: 2021-07-29
- Granted: 2022-04-12
- Earliest claimed: 2018-09-30
- Assignees: Inner Mongolia Yili Industrial Group Co., Ltd.
- Applicants: Inner Mongolia Yili Industrial Group Co., Ltd.
- Inventors: Wei-Hsien Liu; Wen Zhao; Wei-Lian Hung; Ting Sun; Ignatius Man-Yau Szeto; Haotian Feng; Philip Andrew Wescombe; Haoqiu Li
- Web page: https://patentgrep.com/patent/US11298382B2

## CPC

- A61K 35/745: Bifidobacteria
- A61P 19/10: for osteoporosis
- A23L 33/135: Bacteria or derivatives thereof, e.g. probiotics
- A61P 37/00: Drugs for immunological or allergic disorders
- C12N 1/205: Bacterial isolates
- C12R 2001/01: Bacteria or Actinomycetales {; using bacteria or Actinomycetales}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

A Bifidobacterium lactis BL-99 strain capable of enhancing immunity and the use thereof, which belongs to the technical field of microorganisms, is described. The Bifidobacterium lactis BL-99 provided by the present invention is deposited in China General Microbiological Culture Collection Center CGMCC on Apr. 26, 2018 with the deposit number CGMCC No. 15650. The bacteria have gastric acid resistance and intestinal fluid resistance, can significantly promote the growth of Bifidobacterium and Lactobacillus, significantly increase antibody-producing cells and half hemolysis value HC50, activate NK cell activity, and can be used to prepare foods for immunity enhancement. It also has the effects in preventing osteoporosis, increasing blood calcium and/or phosphorus ions, which has a wide range of application prospects.

## Claims

### Claim 1

A Bifidobacterium lactis strain in a freeze-dried form with gastric acid resistance which has a survival rate of viable bacteria of 62% or more when treated in gastric acid at pH 2.5 for 30 minutes, and a survival rate of viable bacteria of 61% or more when treated for 2 hours, wherein the Bifidobacterium lactis strain has a deposit number of CGMCC No. 15650.

### Claim 2 (depends on 1)

The Bifidobacterium lactis strain according to claim 1, wherein the Bifidobacterium lactis strain has intestinal fluid resistance and a survival rate of viable bacteria of 70% or more when treated in small intestinal fluid at pH 6.8 for 2 hours.

### Claim 3 (depends on 1)

A bacteria preparation of Bifidobacterium lactis containing the Bifidobacterium lactis strain according to claim 1, which is a solid bacteria powder in a viable bacteria form or an inactivated form, or a liquid bacteria preparation in a viable bacteria form or an inactivated form.

### Claim 4 (depends on 1)

A food or medicament comprising the Bifidobacterium lactis strain in a freeze-dried form according to claim 1.

### Claim 5 (depends on 1)

A method for regulating the gastrointestinal flora, comprising administering an effective amount of the Bifidobacterium lactis strain according to claim 1 to a subject;
wherein the regulation of the gastrointestinal flora particularly includes: increasing the number of Bifidobacterium and/or Lactobacillus in the intestine, inhibiting Desulfovibrio and/or Enterorhabdus in the intestine, and/or inhibiting Helicobacter and/or Escherichia-Shigella.

### Claim 6 (depends on 4)

The food or medicament of claim 4, wherein the food is a fermented dairy product, cheese, a dairy beverage, a solid beverage or milk powder.